What Is the Value of Treatment for Individual Cancer Patients?

Having myeloma is undeniably expensive. But will new systems of evaluating the cost and efficacy of treatment end up harming myeloma patients by mandating suboptimal care and eliminating access to needed drugs? In his blog this week, IMF Chairman Brian Durie examines these questions. “Individual patient value must be considered,” he writes. “But how do we do that?” Click HERE to read Dr. Durie's blog.
Source: International Myeloma Foundation - Category: Hematology Source Type: news